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1. Introduction
Modeling of human neurodegenerative diseases in animals has led to important advances in
the understanding of pathogenic mechanisms and has opened avenues for curative ap‐
proaches. However, inherent genetic, developmental and anatomical species differences
between humans and animals frequently resulted in imperfect phenotypic correlations
between animal models and human diseases. This might account for the observed hampered
translation of promising preclinical treatment studies in animal models towards clinics.
Pluripotent stem (PS) cells hold considerable promise as a novel tool for modeling human
diseases. Human PS cells include human embryonic stem (hES) cells and induced PS (IPS)
cells. IPS cells are generated via reprogramming of somatic cells through the forced expression
of key transcription factors and share salient characteristics of ES cells, which are derived from
the preimplantation blastocyst.
Both types of PS cells show the capacity to self-renew and to differentiate in vitro and in vivo
into the cell types that make up the human body. This includes the various types of mature
neurons affected by neurodegenerative diseases. The combination of the key advantages of PS
cells allows for the first time to generate large numbers of postmitotic human neurons for
preclinical research in cell culture. In particular, the IPS cell technology opens doors for
intensified research on human PS-derived neurons because, in comparison to hES cells, ethical
concerns can be dispelled. Furthermore, the isolation of patient-derived IPS cell lines from skin
biopsies enables the study of pathogenic mechanisms in human cells carrying relevant
pathogenic allelic constellations.
During recent years the generation of IPS cell lines from human material has become routine.
However, for neurological research a remaining major challenge is to guide in vitro differen‐
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tiation of IPS cells into defined and homogeneous neuronal populations that are required for
modeling neurodegenerative diseases. A hallmark of human neurodegenerative diseases is
the chronic and progressive loss of specific types of neurons: cerebral cortex glutamatergic and
basal forebrain cholinergic neurons in Alzheimer’s disease, midbrain dopaminergic neurons
in Parkinson's disease, striatal GABAergic neurons in Huntington’s disease, motor neurons in
amyotrophic lateral sclerosis and spinal muscular atrophy, cerebellar and peripheral sensory
neurons in ataxias and others. To fully tap into the potential of the IPS technology and to
progress towards a fundamental understanding of the causes of disease selectivity in the loss
of neuron subtypes it will be necessary to establish reproducible and tailored protocols for
differentiation of IPS cells specifically into these neuronal subtypes in vitro.
To date, reprogramming of patient somatic cells into IPS cell-based models has been achieved
for several neurodegenerative diseases. The results show that IPS cells or their derivatives can
display at least some of the cellular and/or molecular characteristics of the respective diseases.
These findings provide first proof for etiological validity of these models. Here, we review the
existing reports demonstrating the generation of human PS cell-based models for neurodege‐
nerative diseases, including also the studies showing the differentiation of human PS cells,
both ES and IPS cells, toward telencephalic neurons (glutamatergic, GABAergic and choliner‐
gic), midbrain dopaminergic neurons, cerebellar neurons, spinal motor neurons and periph‐
eral neurons. We further discuss the perspectives of these cellular models.
2. Generation of human IPS cells
It was in 2006 when the first IPS cells were generated by Takahashi and Yamanaka via
reprogramming of mouse somatic fibroblasts through retroviral transduction with a specific
set of factors [1]. A screen of pluripotency-associated genes yielded a successful combination
of transcription factors, comprising Oct4, Sox2, Klf4 and c-Myc (OSKM), which are commonly
referred to as the ‘Yamanaka factors’. Shortly afterwards, the same group [2], concurrently
with other groups that used different combinations of transcription factors, for example
substituting c-Myc and Klf4 by Lin28 or Nanog [3-5], were able to demonstrate that also
fibroblasts obtained from adult human beings can be induced to undergo the transformation
into PS cells.
Since these first descriptions of IPS cell derivation significant improvements in efficiency of
the protocols, in the quality of the resulting IPS lines and in the depth of their analysis have
been achieved. So far, fibroblasts remain the most popular donor cell type, and were used in
more than 80% of all published reprogramming experiments. Figure 1 illustrates the steps in
generating human IPS cell from skin fibroblasts, as well as cell morphology transition in
culture.
However, other cell sources for inducing pluripotency have been used, amongst them
keratinocytes [6], cord blood cells [7] and mesenchymal stem cells [8] with sometimes higher
efficiency compared to fibroblasts. Furthermore, different combinations of reprogramming
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factors have been developed, ranging in number between two to six [3;4;9]. Each of these
reprogramming factors contributes to the kinetics and efficiency of IPS induction.
Genetic material coding for these reprogramming factors has been introduced into cells via a
variety of methods, comprising genome integrating as well as non-integrating techniques [10].
The most commonly used method for factor delivery is the transduction using retroviruses,
originally with Moloney murine leukemia virus (MMLV), vectors, later on with modified
lentiviral vectors. The efficiency of IPS cell generation using sets of four MMLV-derived
retroviruses expressing single genes from the OSKM set separately is ~0.01% in human
fibroblasts.
Silencing of the permanently integrated transgenes is important because only an IPS cell that
has up regulated the endogenous pluripotency gene network but down regulated the expres‐
sion of the transgenes can be considered fully reprogrammed [11]. Although the use of
retroviruses is efficient and yields reproducible results, random insertional mutagenesis,
permanent alteration of gene expression as well as reactivation of silenced transgenes during
differentiation cannot be excluded. The use of Cre-deletable or dox-inducible lentiviruses has
overcome some of these problems and allows factor expression in a more controlled manner
[12;13]. Other attempts to generate integration-free IPS cells focused on replication-defective
adenoviral vectors, or Sendai viral vectors [14;15] which efficiently deliver foreign genes into
a multitude of cell types.
To avoid the use of viral vectors, direct delivery of episomal vectors (plasmids) as well as
standard DNA transfections using liposomes or electroporation have also been used, but with
low transfection efficiency [16-18]. A polycistronic expression cassette flanked by loxP sites
enabled the excision of the reprogramming cassette after expressing Cre recombinase also in
the non-viral system [19].
Alternatively, Warren et al. [20] developed a novel mRNAs-based system and achieved an
efficient conversion of different human somatic donor cells into IPS cells using a direct delivery
of high dosages of modified mRNAs encoding OSKM and Lin28 packaged in a cationic vehicle.
The efficiency reached with this approach was much higher when compared with other non-
integrative protocols [20].
Recently, a potential role of specific microRNAs (miRNAs) for pluripotency has been eluci‐
dated. The miRNAs from the miR-302 cluster contribute to unique ES cells features such as
cell cycle and pluripotency maintenance [21;22]. Based on these findings protocols for highly
efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency
were reported [23;24]. The resulting miR-IPS cells are subject to a reduced risk of mutations
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Figure 1. Generation of human IPS cells from a skin biopsy.
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and tumorigenesis relative to most other protocols because mature miRNAs function without
genomic integration [23;24].
Finally, another promising possibility of inducing pluripotency is to deliver the reprogram‐
ming factors directly as proteins. To this end Zhou et al. generated recombinant OSKM proteins
fused with a poly-arginine transduction domain [25]. However, this protein-based strategy
induced pluripotency with extremely slow kinetics and poor efficiencies [25].
Apart from the delivery methods of reprogramming factors, other parameters, including
culture conditions and the application of small pharmacological compounds, exert an influ‐
ence on reprogramming efficiency. For example, it has been demonstrated that culturing IPS
cells under hypoxic conditions mimicking the in vivo environment, enhances the efficiency rate
[26]. The addition of small molecules, that either modifies epigenetic states like DNA methyl‐
ation or histone acetylation, or influences specific receptor mediated signaling pathways,
enhances the generation of IPS cells [27-31].
Eventually, the reactivation of endogenous pluripotency genes leads to establishment of cell
lines with pluripotent characteristics. However, even though IPS lines share many character‐
istics with hES cells with regard to morphology and pluripotent gene expression, further
research is required to establish more precisely communalities and differences between hES
and IPS cells. Differences in epigenetic status and in vitro and in vivo differentiation potential
have been reported [32-34].
3. Neuronal differentiation of human PS cells
The in vitro production of neurons from PS cells, following similar mechanism as in vivo
development, involves several sequential steps precisely orchestrated by signaling events
(reviewed in [35;36]).
In vivo, during embryonic development, the initial step is neural induction, the specification
of neuroepithelia from ectoderm cells [37]. When the neuroectodermal fate is determined, the
neural plate folds to form the neural tube, from which cells differentiate into various neurons
and glia [38;39]. The neural tube is patterned along its anteroposterior (A/P) and dorsoventral
(D/V) axes to establish a set of positional cues. The neural plate acquires an anterior character,
and is subsequently posteriorized by exposure to Wingless/Int proteins (Wnt), fibroblast
growth factors (FGF), bone morphogenic proteins (BMP) and retinoic acid (RA) signals to
establish the main subdivisions of the central nervous system (CNS): forebrain, midbrain,
hindbrain, and spinal cord, as well as the neural crest from which the peripheral neurons derive
[40-42]. Therefore, the precursor cells in each subdivision along the A/P axis are fated to
subtypes of neurons and glia depending on its exposure to unique sets of morphogens at
specific concentrations (Figure 2).
As reviewed in Petros et al. [35], specific PS cell-bases protocols, following the principles of
nervous system development, can generate neuronal types with markers consistent with
telencephalic, midbrain, hindbrain spinal cord and peripheral neurons (Table 1).
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Differentiated neural
subtype
PS cell type Key patterning
differentiation factors
References
General telencephalic
neurons
mES cells DKK, LeftyA, Wnt3a, Shh Watanabe et al. (2005)[43],
Li et al. (2009)[44]
Cortical pyramidal neurons mES cells
hES cells
Cyclopamine, Fgf2, RA Eiraku et al. (2008)[45],
Gaspard et al. (2008)[46],
Gaspard et al. (2009)[47],
Ideguchi et al. (2010)[48],
Nat et al 2012[36]
Cortical interneurons mES cells
hES cells
Shh, Fgf2, IGF, Activin Maroof et al. (2010)[49],
Danjo et al. (2011)[50],
Goulburn et al. (2011, 2012)
[51;52], Cambray et al.
(2012)[53], Nat et al
2012[36]
Basal forebrain cholinergic
neurons
hES cells RA, bFGF, FGF8, Shh, BMP9 Wicklund et al (2010)[54],
Bissonnette et al. (2011)[55]
Striatal medium spiny
neurons
mES cells, hES cells Shh, BDNF, DKK1, cAMP,
valproic acid
Aubry et al. (2008)[56],
Zhang et al. (2010)[57],
Danjo et al. (2011)[50]
Floor plate cells hES cells Shh, dual SMAD inhibition Fasano et al. (2010)[58]
Midbrain dopaminergic
neurons
mES cells
hES cells, hIPS cells
Shh, AA, FGF8, bFGF Kawasaki et al. (2000)[59],
Lee et al. (2000)[60], Perrier
et al. (2004)[61], Yan et al.
(2005)[62], Chambers et al.
(2009)[63], Sánchez-Danés et
al. (2012)[64]
Neural Induction Neural Patterning and Specification
Figure 2. Stem cell fates aligned to nervous system development
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Differentiated neural
subtype
PS cell type Key patterning
differentiation factors
References
Cerebellar granule cells mES cells, hES cells Wnt1, Fgf8, RA, BMP 6/7,
GDF7, Shh, JAG1
Salero and Hatten (2007)
[65], Erceg et al. (2010)[66]
Cerebellar Purkinje cells mES cells BMP4, Fgf8 Su et al. (2006)[67], Tao et al.
(2010)[68]
Spinal cord motor neurons mES cells,
hES cells, IPS cells,
hMS cells, hADS cells
Shh, RA, SB431542, Olig2,
HB9
Wichterle et al. (2002)[69], Li
et al. (2005)[70],
Soundararajan et al. (2006)
[71], Lee et al. (2007)[72],
Dimos et al. (2008)[73], Peljto
et al. (2010)[74], Patani et al.
(2011)[75], Park et al. (2012)
[76], Liqing et al. (2011)[77]
Spinal cord interneurons mES cells Wnt3A, Shh, RA, BMP2 Murashov et al. (2005)[78]
Neural crest hES cells, hIPS cells SB431542, noggin, BDNF,
NGF, AA, dbcAMP
Lee et al. (2010)[79],
Menendez et al. (2011)[80],
Goldstein et al. (2010)[81]
Table 1. Neural cell types derived from PS cells to date (modified from Petros et al. 2011[35])
Recognizing that all resulting cell populations, although enriched in specific neurons, remain
heterogeneous, there is a need for additional selection methods to further purify neuronal sub-
type lineages. Whilst a key aim of positionally specifying human neurons is to work towards
the generation of cell-based therapies for diseases that target a sub-population of cells, this
system will be particularly powerful in attempting to understand disease specificity when
applied to patient-derived IPS cells.
4. Neurodegenerative diseases and related models
Neurodegenerative diseases are characterized by the chronic and progressive loss of neuronal
functions in selected neurons. Classical neurodegenerative diseases are Alzheimer’s disease,
Parkinson's disease, Huntington’s disease, amyotrophic lateral sclerosis, spinal muscular
atrophy and ataxias. Other rare diseases such as familial dysautonomia and Fragile-X syn‐
drome contain neurodegenerative aspects as well.
Here we aim to present the main characteristics of these diseases, focusing on their pathogen‐
esis and its reflection into the disease models, including the recent cellular models derived via
IPS cell technology. The most important publications and aspects regarding the IPS cell-related
models for neurological diseases are reviewed in Han et al. 2011[82] and updated for the
neurodegenerative diseases in Table 2.
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Neurodegenerative
disease
Types of
affected
neurons
Histopathology Gene
(Mutation)
Donor
cell
Reprogramming
method
Reported disease-
related
phenotype
References
Alzheimer’s disease Basal forebrain
cholinergic
neurons,
cortical
neurons
Neurofibrillary
tangles, Amyloid
plaque,
Loss of neurons
and synapses
PS1, PS2
mutations;
Sporadic
and APP
duplication
SF LV: OSKLN
RV:OSKM
Increased amyloid
β42 secretion
increased β(1-40)
and phospho-τ
levels
Yagi et al.
(2011)[83],
Israel et al.
(2012)[84]
Parkinson’s disease Midbrain
nigro-striatal
dopaminergic
neurons
Lewy-bodies, loss
of dopaminergic
neurons
idiopathic SF LV: Cre-excisable,
DOX-inducible;
OSK or OSKM
NA Soldner et al.
(2009)[12],
Hargus et al.
(2010)[85]
LRRK2
(G2019S)
SF RV: OSK Increased
caspase-3
activation and DA
neuron death with
various cell stress
conditions
Nguyen et al.
(2011)[86]
PINK1
(Q456X;
V170G)
SF RV: OSKM Impaired stress-
induced
mitochondrial
translocation of
Parkin in DA
neurons
Seibler et al.
(2011)[87]
SCNA
triplication
SF RV: OSKM Increased neural α-
Synuclein protein
levels
sensitivity to
oxidative stress
Devine et al.
(2011)[88],
Byers et al.
(2011)[89]
Huntington’s disease Striatal
GABAergic
medium spiny
neurons,
cortical
neurons
Neural inclusion
bodies, loss of
striatal/cortical
neurons
HTT (CAG
repeats)
SF RV: OSKM Increase in
lysosomal activity
Park et al.
(2008)[4],
Camnasio et
al. (2012)[90]
Amyotrophic lateral
sclerosis
Upper and
lower motor
neurons
Ubiquitinated
inclusion bodies,
loss of
motoneurons
SOD1 SF RV: OSKM, OSK NA Dimos et al.
(2008)[73],
Boulting et al.
(2011)[33]
Spinal muscular
atrophy, type I
Spinal motor
neurons
Loss of anterior
horn cells
SMN1
deletion
SF RV: OSNL
Episomal plasmid
OSKMNL
combinations
Reduced number
of motor neurons,
decreased soma
size, synaptic
defects
Ebert et al.
(2009)[91]
Sareen et al.
(2012)[92]
Friedrich Ataxia Dorsal root
ganglia (DRG)
peripheral
Reduced size of
DRG-neurons,
iron
FXN (GAA
expansion)
SF RV: OSKM GAA repeat
instability
Ku et al.
(2010)[93], Liu
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Neurodegenerative
disease
Types of
affected
neurons
Histopathology Gene
(Mutation)
Donor
cell
Reprogramming
method
Reported disease-
related
phenotype
References
neurons,
cerebellar
neurons
misdistribution,
decreased
myelination
et al. (2010)
[94]
Spinocerebellar Ataxia
Type 3 (Machado-
Joseph Disease)
Cerebellar
neurons,
striatal and
cortical
neurons
Intranuclear
inclusion bodies,
neuronal loss
ATAXIN
3(CAG
expansion)
SF RV: OSKM NA Koch et al.
(2011)[95]
Familial
dysautonomia
Sensory and
autonomic
neurons
Reduced size of
DRG neurons,
reduced number
of non-
myelinated small
fibers and
intermediolateral
column neurons
IKBKAP SF RV: OSKM Defects in
neurogenesis and
migration
Lee et al.
(2009)[96]
Fragile-X syndrome Hippocampal,
cerebellar
neurons
Dendritic spine
abnormalities,
neuronal loss
FMR1
(CGG
repeat)
SF RV: OSKM NA Urbach et al.
(2010)[97]
SF-skin fibroblasts, RV-retroviruses, LV-lentiviruses and NA- not assessed
Table 2. Overview of the iPS the cell-related models for neurodegenerative diseases (modified from Han et al. 2011
[82])
4.1. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease, affecting 35 million
patients worldwide. Clinically, it is characterized by progressive loss of short-term memory
and other cognitive functions toward a state of profound dementia.
AD is histopathologically characterized by neuronal and synapse loss and the appearance of
extracellular amyloid plaques (AP) and intracellular neurofibrillary tangles (NFTs) in affected
brain regions, especially cerebral cortex, hippocampus and basal forebrain [98;99]. The AP and
NFTs form by aggregation of two proteins, beta amyloid (Aβ) and hyperphosphorylated tau
(pTau), respectively [100]. Aβ is formed from the cleavage of the amyloid precursor protein
(APP) into soluble monomers that then aggregate into fibrils and are eventually deposited in
the extracellular space [101]. Tau is a microtubule-associated protein that undergoes hyper‐
phosphorylation and accumulates as intraneuronal inclusions or tangles in the brains of
individuals with AD [100;102].
Degeneration of basal forebrain cholinergic neurons is a principal feature of AD and the
reduction in the level of acetylcholine and choline acetyltransferase activity in the hippocam‐
pus and cerebral cortex has been reported in the brains of AD patients [103;104].
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The majority of AD cases are sporadic; in these cases the major genetic risk factor disease is
the APOE gene. ApoE is synthesized in astrocytes and acts as a ligand for the receptor-
mediated endocytosis of cholesterol-containing lipoprotein particles. Whether ApoE affects
Aβ clearance or operates through its function in lipid metabolism is not yet fully established
[105].
Few familial AD (FAD) cases are an early-onset autosomal dominant disorder. Three genes
have been identified that account for FAD: the first mutations causing Mendelian AD were
identified in the APP gene [106], although mutations in two other genes, presenilin 1 and 2
(PSEN1 and PSEN2), that form the γ-secretase complex components, are more commonly
found. The mutations cause different clinical phenotypes, but for all the aberrant processing
of Aβ led to its aggregation [107].
By classical transgene and knockout approaches, there were established mouse models that
reflect different aspects of AD [108]. Representative models are APP mutant strains (such as
PDAPP, J20, APP23 or Tg2576) with a robust APP/Aβ pathology and tau mutant strains with
NFT formation such as (JNPL3 or pR5). The histopathology in these strains is associated with
behavioral impairment [109].
The modeling of AD via IPS cell technology was recently reported [83;84]. The first study used
AD patient fibroblasts carrying mutations in PS1 and PS2. The IPS cells kept the mutations and
differentiated into neural cells, showing increased amyloid β42 secretion as compared to the
healthy controls [83].
In the second study, IPS cells were generated from both patients with sporadic AD or caring
APP duplication. Interestingly, increased level of both Aβ (1-40) and pTau were detected in
neural cells cultures after neural progenitor expansion of about five weeks, followed by
differentiation of about four weeks [84].
4.2. Parkinson’s disease
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, afflicting
over 6 million people worldwide. Clinically, there are progressive motor dysfunctions
comprising bradykinesia, rigidity and tremor, as well as non-motor features.
Pathologically, PD is identified by intracellular inclusions known as Lewy bodies and dopa‐
minergic neuronal loss that initiates in the substantia nigra.
PD is largely a late onset sporadic neurodegenerative condition. However, 5–10% cases are
familial, transmitted in either an autosomal-dominant or autosomal recessive fashion [110].
A number of genes have been linked to our understanding of pathogenesis. The gene α-
synuclein (SNCA)  product is the major component of the Lewy body in sporadic and in
some  cases  of  autosomal  dominant  types  and  therefore  appears  to  be  central  to  PD
pathophysiology [111;112]. The most common mutation related to autosomal-dominant PD
occurs  in  the  gene  encoding  leucine-rich  repeat  kinase-2  (LRRK2)  [113].  One  missense
mutation, the G2019S mutation, occurs in 5% of familial cases and 1–2% of sporadic cases
of  PD.  Mutations  in  PARK2,  PINK1  and  PARK7  (also  known as  DJ1)  cause  autosomal-
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recessive, early onset PD [114-116]. These genetic discoveries have highlighted the impor‐
tance of the ubiquitin proteasome system, mitochondrial dysfunction and oxidative stress
in PD pathogenesis.
The most common genetic risk factor for PD appears to be heterozygous mutations in the
glucocerebrosidase gene (GBA) [117]. The frequency of heterozygous mutations in GBA reaches
~4% in sporadic PD populations.
Because PD results from the loss of dopaminergic neurons, the prospect of utilizing cell
replacement therapies has attracted substantial interest. Several methods are able to improve
the effectiveness of midbrain dopamine neuron generation and/or retrieval from fetal tissue
and stem cells.
The ability of deriving large quantities of correctly differentiated dopamine neurons makes
stem cells promising cell sources for transplantation in PD; having the transplantation as a
main goal, many studies improved the directed differentiation of PS cells toward dopaminer‐
gic neurons, opening the doors to IPS cell-derived models.
Soldner et al. induced pluripotency in fibroblasts derived from idiopathic PD patients and
controls and subsequently differentiated both into dopaminergic neurons. As they did not find
significant differences between the expression of SNCA or LRKK2 between patients and
controls, they went on to suggest that it might still be necessary to further accelerate PD-
pathology related phenotypes in vitro with neurotoxins such as MPTP, or the overexpression
of PD-related genes such as SNCA or LRKK2 in order to obtain a valid PD model [12].
Hargus et al. [85] used a similar protocol of inducing PS cells for idiopathic PD patients and
controls, and further differentiated them into dopaminergic neurons. Additionally, they
performed intrastriatal transplantation studies into 6-OHDA lesioned rats, demonstrating
improvements in motor symptoms.
Regarding familiar PD, Nguyen et al. [86] used a classical protocol for IPS cells generation and
differentiation and found that IPS cell-derived dopaminergic neurons from patients carrying
a LRRK2 mutation had increased expression of oxidative stress response genes and α-
synuclein protein. The mutant neurons were also more sensitive to caspase-3 activation and
cell death caused by exposure to hydrogen peroxide, MG-132 (a proteasome inhibitor), and 6-
hydroxydopamine than control neurons. The finding of increased susceptibility to stress in
patient-derived neurons provides insights into the pathogenesis of PD and a potential basis
for a cellular screen.
Seibler et al. [87] generated IPS cells form PD patients carrying mutation in PINK1 gene (Q456X;
V170G). They compared the mitochondrial translocation of Parkin in DA neurons under
mitochondrial stress conditions and found a difference between patients and controls, making
a step forward into PD pathogenesis in vitro.
Two recent studies focused on the IPS cell-derived models of PD carrying a triplication in
SNCA genes. Devine et al. showed that the levels of α-Synuclein protein were increased in the
dopaminergic population derived from patients, compared to the healthy controls [88], while
Pluripotent Stem Cells486
Byers et al. focused on the differences in sensitivity to oxidative stress in correlation with this
mutation [89].
4.3. Huntington’s disease
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder resulting
from an expanded CAG triplet repeat in the Huntingtin gene (HTT) on chromosome 4 [118].
This expansion accounts for an attachment of a polyglutamine strand of variable length at the
N-terminus of the protein leading to a toxic gain of function [119]. HD together with eight
other CAG triplet repeat expansion disorders forms the group of PolyQ diseases which share
some specific pathophysiological features [120].
Although the protein huntingtin is ubiquitously expressed in mammalian cells, mainly striatal
GABAergic medium spiny neurons with a dopamine- and cyclic AMP-regulated phospho‐
protein (DARPP-32)-positive phenotype are the most susceptible to neurodegeneration in HD
[121]. As a consequence a prominent cell loss and atrophy in the caudate nucleus and putamen
can be observed. Other brain regions and neuronal subtypes involved in HD comprise the
substantia nigra, hippocampus, cerebellar Purkinje cells and thalamic nuclei [119;122].
One of the histopathological hallmarks of Huntington’s disease, as in other PolyQ disorders
too, is the appearance of nuclear and cytoplasmic inclusion bodies containing the mutant
huntingtin and polyglutamine [123;124]. Much debate regarding the meaning and function of
these inclusions is going on, and although indicative of pathological mutant protein processing
they do not correlate with cellular dysfunction and might even confer a protective role
[125;126].
Numerous studies indicated that wild-type huntingtin might be involved in a variety of
intracellular functions such as in protein trafficking, vesicle and axonal transport, mitochon‐
drial function, postsynaptic signaling; transcriptional regulation, as wells as in anti-apoptotic
pathways [127;128]. Therefore a disruption and detrimental impairment of these various
intracellular pathways is supposed to be the consequence of accumulation of mutant hun‐
tingtin, finally leading to neuronal death.
Over the years, several different HD models had been introduced, ranging from invertebrate
models like Drosophila and C. elegans to various rodent models [129;130]. Genetically
modified animals (especially mouse) models such as transgenic, knock-in and conditional ones
recapitulated some features of HD like neuronal polyglutamine inclusions [131].
The intrastriatal injection of excitotoxic glutamic acid analogues like kainic acid, quinolinic
acid and 3-nitropropionic acid into animals resulted in neuronal cell death similar to the
pathology observed in HD patients [132-134]. They proved to be useful in studying pathoge‐
netic processes involved in the progressive disease course although some limitations regarding
the selective neuronal cell loss as well as aggregate formation properties and variable pheno‐
types have to be kept in mind.
Transplantation studies in animal HD models aimed at providing neuroprotective support or
intended to replace damaged and lost neuronal subtypes. Successful application of stem cell-
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based therapy in animal models of HD with functional recovery has been reported [135;136].
Different cell types ranging from neural stem/progenitor cells from mouse and rat or human
fetal brain tissue to bone marrow and mesenchymal stem cells have been transplanted into
excitotoxic animal HD models[137].
In order to facilitate research in the HD field with human material, Bradley et al. [138] derived
four hES cell lines containing more than 40 CAG repeats from donated embryos obtained
through an informed consent. Those hES cells were able to differentiate in to neuronal cells
expressing the mutant huntingtin protein.
The first HD-IPS cell lines were successfully generated by Park et al. from patient with a 72
CAG repeat tract using the classical lentiviral vectors [4]. In a subsequent study Zhang et al
used these patient-specific IPS cells in order to generate HD specific neural stem cells that were
then differentiated into striatal neurons. Besides a stable CAG repeat expansion in all patient-
derived cells, an enhanced caspase 3/7 activity was found.
A second group successfully generated HD-specific IPS cells via lentiviral transduction of
transcription factors and was able to demonstrate a stable CAG triple repeat length in all IPS
cell clones as well as in IPS cell-derived neurons. Interestingly, they observed an enhanced
lysosomal activity in IPS cells and their derived neuronal populations [139].
4.4. Motor neuron diseases
Motor neurons (MNs) are essential effector cells for the control of motor function. Degenerative
MN diseases, such Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS)
are devastating disorders due to a selective loss of MNs, which in turn leads to progressive
muscle atrophy and weakness.
SMA is the most common form of degenerative motor neuron disease in children and young
adults, characterized by the selective degeneration of lower MNs in the brainstem and spinal
cord [140]. SMA is a classical autosomal recessive disorder with the vast majority of SMA cases
caused by homozygous mutations in the gene named Survival of Motor Neuron-1 (SMN1)
[141;142].
Interestingly, in humans the SMN exists in a telomeric copy, SMN1, and several centromeric
highly homologous copies, SMN2, with both genes being transcribed [143]. Due to the fact that
the vast majority of SMN2 transcripts lack an exon due to a splicing defect, it is only partially
and poorly able to compensate for reduced SMN1 levels [144;145].
SMN is a ubiquitously expressed gene involved in the biogenesis of small nuclear ribonucleo‐
proteins important for pre-mRNA splicing, but might also have a specific role in RNA transport
in neurons [146]. However, it remains to be elucidated how a deficiency in SMN is responsible
for the selective degeneration of lower motor neurons [147].
Several experimental models have been used to study the putative cellular and molecular
processes involved in SMA. Mouse models have become the most often used, albeit lacking
the duplication of the SMN gene in humans. As a consequence, homologous recombination
technology of the Smn locus in mice leads to complete depletion of the SMN protein, causing
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early embryonic lethality [148], which has necessitated generating transgenic mice that harbor
human SMN2 [149;150] on a SMN-/- background. Although this model provided invaluable
protein and disease information, reflecting a gene dosage–dependent phenotype similar to
severe forms of SMA, these mice normally die shortly after birth.
It was in 2009 when patient-derived IPS cells were used for the first time to model SMA [91].
Therefore, skin fibroblasts from a three-year old child with SMA as well as from the unaffected
mother were successfully reprogrammed via transduction with lentiviral vectors comprising
OCT4, SOX2, NANOG, and LIN28. Characterization of the obtained IPS cells demonstrated
lack of SMN1 expression and reduced levels of the full-length protein compensated by SMN2.
Patient and control IPS cells were further differentiated into neurons. Within these neural
cultures, significant differences regarding the number of motoneurons as well as their soma
size and synapse formation ability could be observed between patient-specific and control
cells, therefore reflecting disease-specific phenotypes. Furthermore, valproic acid and tobra‐
mycin, two drugs known to increase full-length SMN mRNA levels from the SMN2 locus, were
tested on this human cellular SMA model. A 2-3-fold increase in SMN protein expression in
SMA-IPS cells and an increased nuclear punctuate localization of SMN protein were found.
In a continuative experiment, Sareen et al [92] generated SMA-specific IPS cells using a virus-
free plasmid-based approach with subsequent differentiation of IPS cells into NSCs and further
MN differentiation. Besides the already described SMA-specific phenotypes, increased
apoptosis was detected in SMA-specific cells, which might be another potential target for
therapeutic intervention.
ALS, also known as Lou Gehrig’s disease is the most common form of MN disease; it as a
rapidly progressing, fatal disorder, usually as a result of respiratory failure. In contrast to SMA,
it is characterized by a progressive loss of both upper and lower motor neurons in the cerebral
cortex, brainstem and spinal cord. Two forms of ALS can be distinguished, the more frequent
sporadic form accounts for about 90% of cases and the less common familial form (FALS) for
the remaining 10% [151].
Mutations in the Cu/Zn superoxide dismutase 1 (SOD1) gene are responsible for about 20% of
the familial cases [152]. Recently, several other gene mutations were identified as important
causing typical FALS, such as the gene encoding the TAR DNA-binding protein 43 (TDP-43)
[153]. The role of TDP-43 was first suspected when it was identified as one of the major
constituents of the intra-neuronal inclusions characteristically observed in ALS and in
frontotemporal lobar degeneration–ubiquitin (FTLD-U); [154]. Subsequently, mutations in the
TARDBP gene encoding TDP-43 were identified in some FALS [153].
On macroscopic and microscopic examination of the nervous system in ALS variable neuronal
inclusion bodies in lower motor neurons of the spinal cord and brain stem can be detected
[155]. Morphologically these inclusions are reliably demonstrated only by their immunoreac‐
tivity to ubiquitin, and have been reported in both sporadic and familial cases and are present
in transgenic models of ALS. It is now well established that ALS is typically characterized by
the presence of these inclusion bodies.
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Furthermore, it has been reported that an ALS genotype in glial cells (astrocytes) has an effect
on the survival of motor neurons and contributes a crucial role in motor neuron degeneration
[156].
ALS research has focused mainly on models of the familial SOD1-mediated form, although all
forms of ALS share striking similarities in pathology and clinical symptoms. A toxic gain of
function of this enzyme with the exact mechanism still unclear is thought to be responsible
which subsequently results in mitochondrial dysfunction, oxidative damage, glutamate
excitotoxicity, protein aggregation, proteasome dysfunction, cytoskeletal and axonal transport
defects and inflammation [151;157].
Transgenic mice or rats overexpressing mutant SOD1 develop MN degeneration with pro‐
gressive muscle weakness, muscle wasting and reduced life span [158]. Furthermore, mutant
SOD1 as well as TDP-43 models have been generated in zebrafish and C. elegans, mimicking
at least some of the pathological hallmarks (e.g. selective vulnerability of MN and MN
dysfunction) and therefore making them suitable for genetic and small compound screening
[157;159].
Transgenic ALS models have also already been utilized for stem cell therapies by transplanting
different types of cells comprising human as well as rodent fetal neural stem and progenitor
cells, umbilical cord blood stem cells, mesenchymal stem cells and bone marrow. In some of
the studies, a moderate improvement of motor function and a delayed disease progression
could be observed [160]. However, the translation of stem cell transplantation therapies into
clinical trials did not show any therapeutic benefit in ALS patients.
In order to get more insight into human pathophysiology, Dimos et al. [161] were the first to
generate ALS-patient specific IPS cells using retroviral transduction of the classical Yamanaka
factors OSKM. They successfully obtained IPS cells from an 82-year old sibling suffering from a
familial form of ALS with a mutation in the SOD1 gene. Subsequently, patient-specific IPS cells
were forced to differentiate into MN and glia. Due to the fact that more than 90% of ALS cases
are sporadic, patient-specific IPS cell models from sporadic ALS might overcome this draw‐
back through the integration of the genetic as well as environmental individual background.
4.5. Ataxias
The degenerative ataxias are a group of hereditary or idiopathic diseases that are clinically
characterized by progressive ataxia resulting from degeneration of cerebellar-brainstem
structures and spinal pathways [162].
Autosomal recessive cerebellar ataxias are heterogeneous, complex, disabling inherited
neurodegenerative diseases that become manifest usually during childhood and adolescence.
Friedreich Ataxia (FRDA), an autosomal-recessive ataxia, is the most common inherited ataxic
disorder in the white Caucasian population with a prevalence of 2-4/100,000 and with an age
of onset in the teenage years. Clinical characteristics include progressive ataxia of gait and
limbs, dysarthria, muscle weakness, spasticity in the legs, scoliosis, bladder dysfunction, and
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loss of position and vibration sense [163;164]. Cardiomyopathy and diabetes mellitus are
systemic complications in some patients [165].
FRDA is caused in 96% of individuals by a GAA triplet expansion in the first intron of the
Frataxin (FXN) gene on chromosome 9q13 [166]. The mutation leads to transcriptional
silencing as a result of heterochromatin formation, adoption of an abnormal DNA-RNA hybrid
structure, or triplex DNA formation [167] with reduced Frataxin protein expression. About 4%
of the individuals affected with FRDA are compound heterozygous. Disease-causing expand‐
ed alleles present with 66 to 1700 GAA repeats with the majority ranging from 600 up to 1200
GAA repeats [166;168]. Major neuropathologic findings comprise a degeneration of dorsal root
ganglia (DRG), with loss of large sensory neurons, followed by degeneration of posterior
columns, corticospinal tracts and spinocerebellar tracts, and the deep nuclei in the cerebellum
[165;169].
The gene product Frataxin is a ubiquitously expressed and evolutionary conserved mitochon‐
drial protein that has been proposed to exhibit roles in mitochondrial iron metabolism and the
production of iron-sulfur (Fe-S) clusters.
Several FRDA disease models, from yeast, C. elegans and Drosophila to mice have been used
to get more insight into the disease [170;171]. Viable transgenic mouse models were generated
through conditional gene targeting [172] which have been crucial in the development as
models for FRDA, although some with ambiguous results. The complete knock-out of Frataxin
resulted in embryonic lethality [173], whereas conditional mouse models under the control of
different promoters were capable to recapitulate some of the disease phenotypes [174]. In order
to circumvent the non-physiologic complete loss of Frataxin at a specific time point in
conditional models, GAA based mouse models were introduced [175;176], shedding more light
on tissue-dependent GAA dynamics and putative pathophysiologic pathways.
Despite a general genotype-phenotype correlation it is not possible to predict the specific
clinical outcome in any individual based on GAA repeat length. The inherent variability in
FRDA may be caused by genetic background, somatic heterogeneity of the GAA expansion
[177;178], and yet other unidentified factors.
Therefore, FRDA-IPS cell lines have already been established by Ku et al. [93] and Liu et al.
[94]. Data showed that, although a specific disease-related phenotype was not reported, these
FRDA IPS cells were able to recapitulate some of the molecular genetic aspects of FRDA,
including the phenomenon of repeat-length instability, epigenetic silencing of the FXN locus
and low levels of Frataxin expression [93].
With regard to GAA repeat instability, IPS cells showed repeat expansions whereas parental
fibroblasts did not [93]. Instability was specific to the abnormally expanded FXN as GAA
expansions in normal FXN alleles or at two unrelated loci with short GAA repeats remained
unchanged. To understand the mechanism of instability in this IPS cell system, analysis of
differences in mRNA expression showed that MSH2, a critical component of the DNA
mismatch repair (MMR) machinery and important for mediating repeat-length instability, was
highly expressed in FRDA-IPS cells relative to donor fibroblasts. ShRNA-mediated silencing
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of MSH2 resulted in shorter repeat lengths suggesting that FRDA IPS cells could be a useful
system to evaluate the mechanisms of repeat expansions and contractions in disease.
GAA repeat mutations are unstable and progressive and postnatal instability occurs in various
tissues throughout life. For example, large GAA repeat expansions are especially prominent
in the dorsal root ganglia of FRDA patients, which harbor cell bodies of sensory neurons, a
neuronal subtype especially affected in FRDA [179].
Given FRDA-IPS cells can be directed to differentiate into sensory neurons, as well as cardio‐
myocytes [94], the presence and mechanisms of tissue-specific expansion should be testable.
The major focus of FRDA IPS cell differentiation research is currently focused on generating
appropriate disease-relevant cell types. For example, sensory neurons of the DRG are crucially
affected in individuals with FRDA.
The autosomal dominant Spinocerebellar Ataxias (SCAs) comprise a genetically and clinically
heterogeneous group of inherited neurodegenerative progressive disorders affecting various
parts of the CNS. The number of known SCAs continues to grow and comprises meantime
over 30 entities.
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is the
most frequent entity among the autosomal dominantly inherited cerebellar ataxias in Europe,
Japan, and the United States [180].
Genetically, SCA3 belongs to the group of CAG-triple repeat disorders, also known as PolyQ-
disorders due to abnormally long polyglutamine tracts within the corresponding protein. The
majority of patients suffering from SCA3 carry one allele of the ataxin3 (ATXN3) gene with
60–82 CAG repeats and a second allele containing the normal number of repeats, which is
usually between 13 and 41 [181].
As in most of these polyglutamine diseases, patients with a repeat expansion above a critical
threshold form neuronal intranuclear inclusion bodies, one important hallmark of polyQ
diseases [182]. Further neuropathological features include a depigmentation of the substan‐
tia nigra as well as a pronounced atrophy of the cerebellum, pons and medulla oblongata,
altogether culminating in an overall reduced brain weight compared to healthy individu‐
als [183].
As most of the PolyQ disease proteins are ubiquitously expressed it still remains unclear
why only specific neuronal cell populations are prone to neurodegeneration. Many animal
models, like rodents, C.elegans and Drosophila, overexpressing specific forms of ATXN3 are
available  to  study the molecular  and phenotypic  aspects  of  MJD involving aggregation,
proteolysis and toxicity of expanded ATXN3, as well as the apparent neuroprotective role
of wild-type ATXN3 [184].
Kakizuka’s group was the first to demonstrate neurodegeneration and a neurological pheno‐
type in mice transgenic for the CAG repeat expansion [185]. Mouse models further provided
evidence for the subcellular site of pathogenesis, the processing and trafficking of the mutant
protein in order to cause cellular dysfunction and neuronal cell loss.
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While some of the transgenic mouse models expressing the full-length ATXN3 under control
of various exogenous promoters were able to mimic some aspects of the disease, they all
overexpress only a single isoform of ATXN3. Taken this into account, a YAC MJD transgenic
model was established which more closely recapitulates the human disease as all elements,
including regulatory regions of the gene, are present [186]. Research in animal models of SCA
has now begun to focus on therapeutic strategies to prevent protein misfolding and aggrega‐
tion in polyglutamine diseases by overexpressing chaperones.
Koch et al [95], investigated the formation of early aggregates and their behavior in time by
making use of patient- specific IPS cell-derived neurons. They demonstrated that MJD-IPS cell
derived neurons constitute an appropriate cellular model in the study of aberrant human
protein processing. Moreover, they concluded that neurons are able to cope, at least in the
beginning, with the aggregated mutant material and cytotoxicity evolved over time. Besides,
a key role for the protease calpain in ATXN3-aggregation formation was found which could
further display a putative benefit of calpain inhibitors.
4.6. Familial dysautonomia and fragile X syndrome
Familial Dysautonomia (FD), also known as Riley-Day Syndrome or Hereditary Sensory
Autonomic Neuropathy (HSAN) Type III, is a rare autosomal recessive disease mostly
occurring in persons of Ashkenazi Jewish descent [187]. The disease is characterized by
degeneration of sensory and autonomic neurons, leading to severe and often lethal central and
peripheral autonomic perturbations, as well as small-fiber sensory dysfunction. The underly‐
ing mutation induces a splicing defect in the IkB kinase complex-associated protein (IKB‐
KAP) gene, which results in tissue-specific loss of function or reduced levels of the IKAP
protein [188]. Individuals affected with FD suffer from incomplete neuronal development as
well as progressive neuronal degeneration with the sensory and autonomic neurons mainly
affected [189].
Although the exact function of the IKAP protein is not clearly understood, researchers have
identified IKAP as the scaffold protein required for the assembly of a holo-elongator complex
[190]. As a consequence, an impaired transcriptional elongation of genes responsible for cell
motility is thought to be the cause for the observed cell migration deficiency in FD neurons
[191]. Besides, the IKAP protein is also thought to be involved in other cellular processes,
including tRNA and epigenetic modifications and exocytosis [192].
To better understand the function of IKAP, Dietrich et al. [193] created a mouse model with
two distinct alleles that result in either loss of Ikbkap expression, or expression of the mutated
truncated protein. Besides, a humanized IKBKAP transgenic mouse model for FD had been
created that recapitulated the tissue-specific splicing defect, i.e. skipping of exon 20, in nervous
tissues [194].
In order to untangle the tissue-specific pattern of IKBKAP mRNA splicing in FD, Boone et al.
[195] created a human olfactory ecto-mesenchymal stem cell (hOEMSC) model of FD. It has
been shown that these multipotent hOE-MSCs exhibit the potential to differentiate in vitro into
neurons, astrocytes, and oligodendrocytes as well as other cell types [196]. Classical features
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of the FD phenotype, like the expression of the mutant IKBKAP transcript, notably lower
IKBKAP levels as well as an impaired migration, were observed. Besides, drug testing
experiments with kinetin, which had been shown effective in previous studies [197], had the
potential to correct the splicing in a dose-dependent manner in FD hOE-MSCs.
Furthermore, IPS cells were generated from a patient with FD using the classical Yamanaka
factors and subsequently differentiated into neural crest derivatives [96]. This was one of the
earliest reports of a phenotype for a neurological disease to be modeled with IPS cells. FD-IPS
cell derived neural precursors showed particularly low levels of IKBKAP, mis-splicing of
IKBKAP, and defects in neurogenic differentiation and migration behavior. Again, the plant
hormone kinetin was tested as a candidate and showed a reduction of mutant IKBKAP splice
forms, an improvement in neuronal differentiation, but not in cell migration.
Fragile-X (FX) syndrome belongs to the autism spectrum disorders, and is the most common
cause of inherited mental retardation with a prevalence of 1/3600 [198]. In the vast majority of
cases, the disease is caused by a silencing of the FMR1 gene due to a CGG repeat expansion
(>200 repeats) in the 5-UTR of the FMR1 gene [199]. The FMR1 gene codes for the cytoplasmic
protein FMRP, which has RNA-binding properties and is thought to play a role in synaptic
plasticity and dendrite maturation. This could be demonstrated in histopathological studies
of FX where dendritic spine abnormalities were found [200].
Several animal models revealed important insights into the role of the FMR protein. A
Drosophila model showed a role of FRMP in the regulation of the microtubule network [201].
The first fmr1 KO mouse model was generated shortly after the discovery of the disease-
causing gene and showed classical clinical features of FXS like macroorchidism, learning
deficits, and hyperactivity[202].
Although current mouse models for FX syndrome are useful for studying the clinical pheno‐
type, they do not recapitulate the hallmark, i.e. silencing of the FMR1 gene due to the triplet
repeat expansion [203]. Loss of function studies using morpholino antisense oligonucleotides
in zebrafish revealed a function of FMRP in terms of normal axonal branching.
Primary and transformed cell cultures obtained with an unmethylated full mutation in the
FMR1 showed that the CGG expansion per se does not block transcription [204]. In undiffer‐
entiated human FX embryonic stem cells (FX-ES cells) derived from affected blastocyst-stage
embryos, FMR1 is expressed and gene silencing occurs only upon differentiation [205]
indicating a developmentally dependent process.
Recently, Urbach et al. [97] generated FX-IPS cell lines from three patients. In contrast to FX-
ES cells, FX-IPS cells presented with a transcriptionally silent FMR1 gene, both in the pluri‐
potent and differentiated states. This was reflected by corresponding epigenetic
heterochromatin modifications in the gene promoter. IPS cells were further differentiated into
neural derivatives and different potential epigenetic modifiers were tested. Amongst those, 5-
azacytidin showed an upregulation of FMR1 transcripts both in pluripotent as well as neuronal
FX-cells.
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5. Conclusions and perspectives
In this chapter we have described the first successful attempts to harness the IPS technology
for the generation of models for neurodegenerative diseases of the human nervous system.
The key advantage of IPS based models over animal models is that they offer researchers for
the first time a realistic chance to work in cell culture with large numbers of primary human
cells that closely resemble the postmitotic neurons affected by neurodegeneration.
The first studies in which patient-derived disease-susceptible cellular phenotypes were
compared with those of cells derived from healthy individuals, provide strong indications that
such cellular models reflect key pathological molecular and cellular aspects of the neurological
diseases. Therefore a future concept for patient-derived cellular models will be to correct
neuronal malfunctions diseases by in vitro treatment of affected cells. A first such attempts
aspect has been in the SMA models [91].
These in vitro treatments will include hypothesis driven approaches based on knowledge about
pathophysiological mechanisms. Equally important patient derived lines will be used as in
vitro assays for the screening of compound libraries. Drug safety screens with IPS cell-derived
neurons will help to reduce the animal dependency of the current drug development pipeline.
Finally, IPS cell technology will be an important driver of personalized medicine. Prior to
patient treatment drug types and doses can be tested on patient-derived IPS cells or differen‐
tiated progenies in order to tailor a personalized curative approach according to the individual
genetic and cellular profile.
There is even hope that the novel approach bypasses the laborious, time-consuming and
expensive IPS cell generation by direct reprogramming of mouse and human somatic cells into
functional neurons, called induced neurons (INs) [206;207], will come to fruition. Several
groups have already generated dopaminergic INs [208;209] and motor INs [210]. Patient-
specific INs could be generated to enhance the study of developmental disorders and other
neurological diseases [211]. The significant decrease in time and resources to derive neurons
directly from somatic cells justifies further investigation into this strategy.
But despite the enormous potential of IPS cell derived neurons for studies involving cell
biological, physiological and pharmacological methods important question remain to be
solved. One major drawback is that we still know very little about the specific cell biology of
IPS cells and even less of their neuronal derivatives. This includes for example changes in
chromatin structure and epigenetic signatures that accompany the reprogramming process.
And there is exceedingly little information about membrane physiology of the IPS cell- derived
neurons. Electrophysiological recordings and parallel studies of synaptic proteins and ion
specific channel composition should be a focus of future research.
We have already pointed out the difficulties to design specific differentiation protocols for
specific neuronal populations from IPS cells. The underlying hypothesis for all existing
protocols is that cells should be guided through a shortcut version of embryonic development.
A hindrance for progress in this regard is the lack of specific information of human embryonic
development since most of our knowledge about vertebrate brain development derives from
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work with rodents. Recent reports about surprising differences between rodent and human
developmental processes emphasize the demand for further comparative studies of human
and rodent brain development [36;44].
The biggest limitation of IPS cell models is that they do not offer straightforward possibilities
to study functions of neurons in vivo, as parts of the brain circuitries that regulate higher brain
functions and organismic behavior. Obviously, cellular models alone will never be able to
produce clinically important read-outs, such as memory dysfunction and behavioral changes
in AD, tremor, bradykinesia, and rigidity in PD, or reduced forced vital capacity, swallowing
dysfunction, dysarthria, or limb motor impairment in ALS. Therefore, in the foreseeable future
research on neurodegenerative diseases will combine in vitro and in vivo approaches. In vivo
transplantation of stem cell derivatives in relevant animal models could bring additional
information regarding the potential of hIPS cells for in vivo differentiation and their survival
in a pathological brain environment. This is first exemplified in a study of directed differen‐
tiation of IPS cells to midbrain neurons and their transplantation into a rat model of PD, which
led to functional recovery [64].
This result and many others that we summarized in this chapter raise hopes that IPS cells
derived from affected and healthy human individuals will provide a unique opportunity to
gain insights into the human pathophysiology and pharmacologic responses in yet incurable
neurodegenerative diseases.
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